Gonadprelin Analogues Treatment FAQ
How do they work?The symptoms caused by fibroids tend to diminish after menopause as blood flow to the uterus and fibroids decreases and the fibroids subsequently shrink. There are a number of drugs that will mimic menopause by blocking the hormone (gonadotrophin releasing hormone GnRH) that is responsible for the production of oestrogen, sale the female hormone. These are known as gonadorelin analogues or GnRH agonists. They induce rapid menopause by blocking oestrogen production with the result that the blood levels to the fibroid drop and the fibroids get smaller, side effects as they would after menopause. This is only a temporary treatment for fibroids, sometimes used to reduce them before surgery or menopause. However, drugs should not be used for longer than 6 months.
What are the side effects?The side effects can be extremely unpleasant, which is why some gynaecologists do not use these drugs. They mimic menopausal symptoms -
How effective is it?Drug treatment is only a temporary measure before surgery. Fibroids will return to their normal size 24 weeks after treatment stops.
Questions to ask your doctor
|
You are here:
Our Survey and Guidelines
NICE Review of their Clinical Guidlines on Heavy Menstrual Bleeding carried out by part of RCOG is launched 14th March'18. FEmISA condemns it as unsafe for women - see our press release. FEmISA queries NICE's figures on hysteroscopy. This is regressive - see our concerns and our submission to this NICE eEview.
See FEmISA's new report on NICE compliance and patient choice for fibroid treatments part of this report was included in the recent APPG On Women's Health report Informed Choice? Giving women control of their healthcare
Thanks to all who took part in our survey about the information and choices for their fibroid treatment. Please click here for the Patient Information and Choice Survey report and here for our report on access to UFE treatment with The Medical Technology Group and All Party Parliamentary Group on Improving Patient Access to Medical Technologies.
